InvestSMART

PainChek Ltd (ASX:PCK)

ALERT: Price-sensitive ASX Announcement for PCK
Current share price for PCK : $0.100 -0.05 (-33.33%)+
Announcement
Release
14 Apr 2026 9:19AM
Price at Release
$0.150
Full Release
download
Summary
PainChek Ltd has entered into a significant Master Services Agreement with Sabra Health Care REIT, Inc., a major U.S.-based healthcare real estate investment trust (REIT), to deploy its AI-powered pain assessment application, PainChek, across Sabra’s extensive network of long-term care and senior housing facilities in North America. This agreement aims to cover up to 20,000 beds, representing a strategic commercial milestone for PainChek as it expands its presence in the North American market following FDA approval in 2025. Sabra will fund the deployment across its 329 facilities, which will facilitate the implementation and reduce adoption barriers for operators. The pricing of the PainChek solution is set between $55 and $75 USD per bed per annum. This model is also considered a blueprint for potential partnerships with other large US-based REITs.
Key Points
  • PainChek Ltd's agreement with Sabra Health Care to deploy PainChek across 329 facilities.
  • Sabra Health Care REIT will fund the deployment for up to 20,000 beds.
  • Pricing set at $55-$75 USD per bed per annum, with lower pricing for long-term agreements.
  • The deployment model is capital-light and scalable across other REITs.
  • This marks a significant step for PainChek's expansion in North America post-FDA approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.